![]() |
市場調查報告書
商品編碼
1479962
2024 年全球生技投資成長機會Growth Opportunities in Global Biotech Investment, 2024 |
領先生物製藥公司的顛覆性技術和投資組合重組確保了生物技術投資的成長潛力
在這份分析中,Frost & Sullivan 提供了有關生物技術併購和創業投資(VC) 投資的重要見解,確定了生物技術領域的促進因素、挑戰、預測和主要趨勢。該分析還確定了行業參與者可以利用的成長機會。
為了了解 2024 年以後的趨勢前景,本分析評估了 2019 年至 2023 年的策略和金融投資、併購)、創投和私募股權(PE)。 Frost & Sullivan 收集了整個生態系統的總數。然而,僅分析不涉及小分子資產的生物技術/生物製藥交易。本分析的範圍是以2023年為基準年的全球,並包含截至2028年的預測。
該評估不包括債務或未決事項。由於資料基於二手資訊,因此處理的數量和金額可能會有所不同。同樣,生物技術的定義也各不相同。一些資訊來源在公告日期記錄併購交易,資訊來源記錄交易進度的里程碑,還有資訊來源記錄交易結束後的總金額。
Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments
In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.
To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.
This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.